Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver

C. Schmitt1,2,3, H. Lenglet2,3, A. Yu4, C. Delaby5, A. Benecke6,7, T. Lefebvre1,2,3, P. Letteron2, V. Paradis2,8, S. Wahlin9, S. Sandberg10,11, P. Harper12, E. Sardhi12, A. K. Sandvik13, J. R. Hov14, A. K. Aarsand10,11, L. Chiche15, C. Bazille16, J.-Y. Scoazec17, J. To-Figueras18, M. Carrascal19, J. Abian19, A. Mirmiran2,3, Z. Karim2,3, J.-C. Deybach1,2,3, H. Puy1,2,3, K. Peoc’h2,3,20, H. Manceau2,3,20 & L. Gouya1,2,3

1From the Centre Français des Porphyries, Hôpital Louis Mourier, Assistance publique-Hôpitaux de Paris (AP-HP), Colombes; 2Centre de Recherche sur l’Inflammation (CRI), UMR1149 INSERM, Université Paris Diderot, site Bichat; 3Laboratoire d’excellence, GR-Ex, Paris; 4STIM CNRS ERL 7368, Physiologie des Cellules Cardiaques et Vasculaires, Tours; 5Laboratory for Clinical Biochemistry and Proteomics, Institute for Regenerative Medicine and Biotherapy (IRMB), CHU de Montpellier and Université Montpellier, Montpellier; 6Centre National de la Recherche sur l’Inflammation (CRI), UMR1149 INSERM, Université Paris Diderot, site Bichat; 7Laboratoire d’excellence, GR-Ex, Paris, Physiologie des Cellules Cardiaques et Vasculaires, Tours; 8Laboratory for Clinical Biochemistry, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital; 9Laboratory for Clinical Biochemistry, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital; 10Laboratory for Clinical Biochemistry, Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital; 11Department of Global Health and Primary Health Care, University of Bergen, Bergen, Norway; 12Porphyria Centre Sweden, Centre for Inherited Metabolic Diseases, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; 13Department of Gastroenterology and Hepatology, St. Olav’s University Hospital, Trondheim; 14Department of Transplantation Medicine, Norwegian PSC Research Center and Section of Gastroenterology, Oslo University Hospital and University of Oslo, Oslo, Norway; 15Centre Hospitalier Universitaire Bordeaux, Chirurgie Hépatobiliaire et Pancréatique, Maison du Haut Lévêque, Bordeaux; 16Service d’anatomopathologie, Institut Gustave Roussy, Villejuif, France; 17Biochemistry and Molecular Genetics Department, Hospital Clinic, IDIBAPS, Barcelona, Spain; and 18Laboratory for Clinical Biochemistry, Hospital Beaujon, AP-HP, Clichy, France

Abstract. Schmitt C, Lenglet H, Yu A, Delaby C, Benecke A, Lefebvre T, Letteron P, Paradis V, Wahlin S, Sandberg S, Harper P, Sardhi E, Sandvik AK, Hov JR, Aarsand AK, Chiche L, Bazille C, Scoazec JY, To-Figueras J, Carrascal M, Abian J, Mirmiran A, Karim Z, Deybach JC, Puy H, Peoc’h K, Manceau H, Gouya L (Hôpital Louis Mourier, Assistance publique-Hôpitaux de Paris (AP-HP), Colombes; Université Paris Diderot, site Bichat; Centre de Recherche sur l’Inflammation (CRI), UMR1149 INSERM, Université Paris Diderot, site Bichat; Laboratoire d’excellence, GR-Ex, Paris, Physiologie des Cellules Cardiaques et Vasculaires, Tours; Institute for Regenerative Medicine and Biotherapy (IRMB), CHU de Montpellier and Université Montpellier, Montpellier; Institut des Hautes Études Scientifiques, Bures-sur-Yvette, France; Université Paris Diderot, site Bichat; GR-Ex, Paris, Physiologie des Cellules Cardiaques et Vasculaires, Tours; Institute for Regenerative Medicine and Biotherapy (IRMB), CHU de Montpellier and Université Montpellier, Montpellier; Institut des Hautes Études Scientifiques, Bures-sur-Yvette, France; Université of Washington School of Medicine, Seattle, USA; Hôpital Beaujon, AP-HP, Clichy, France; Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden; Norwegian Porphyria Centre (NAPOS), Haukeland University Hospital; University of Bergen, Bergen, Norway; Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden; St. Olav’s University Hospital, Trondheim; Oslo University Hospital and University of Oslo, Oslo, Norway; Maison du Haut Lévêque, Bordeaux; Centre Hospitalo-Universitaire de Caen, Caen; Institut Gustave Roussy, Villejuif, France; Hospital Clinic, IDIBAPS, University of Barcelona; IIBB-CSIC, IDIBAPS, Barcelona, Spain; Hôpital Beaujon, AP-HP, Clichy, France). Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver. J Intern Med 2018; 284: 78–91.

Background. Acute intermittent porphyria (AIP) is an inherited disorder of haem metabolism characterized by life-threatening acute neurovisceral attacks due to the induction of hepatic δ-aminolevulinic acid synthase 1 (ALAS1) associated with hydroxymethylbilane synthase (HMBS) deficiency. So far, the treatment of choice is hemin which represses ALAS1. The main issue in the medical care of AIP patients is the occurrence of debilitating recurrent attacks.

Objective. The aim of this study was to determine whether chronic hemin administration contributes to the recurrence of acute attacks.

Methods. A follow-up study was conducted between 1974 and 2015 and included 602 French AIP patients, of whom 46 had recurrent AIP. Moreover, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of Hmsb−/− mice chronically treated by hemin and extended the investigations to five explanted livers from recurrent AIP patients.

Results. The introduction of hemin into the pharmacopeia has coincided with a 4.4-fold increase in the prevalence of chronic patients. Moreover, we
showed that both in animal model and in human liver, frequent hemin infusions generate a chronic inflammatory hepatic disease which induces HO1 remotely to hemin treatment and maintains a high ALAS1 level responsible for recurrence.

**Conclusion.** Altogether, this study has important impacts on AIP care underlying that hemin needs to be restricted to severe neurovisceral crisis and suggests that alternative treatment targeting the liver such as ALAS1 and HO1 inhibitors, and anti-inflammatory therapies should be considered in patients with recurrent AIP.

**Keywords:** acute intermittent porphyria, haem oxygenase 1, hemin, inflammation, iron overload.

---

**Introduction**

Acute intermittent porphyria (AIP), the most common acute hepatic porphyria, is an autosomal dominant disease that occurs as a result of a 50% decrease in the activity of hydroxymethylbilane synthase (HMBS), the third enzyme of the haem biosynthesis pathway [1]. AIP is characterized by the intermittent occurrence of neurovisceral attacks, which typically consist of severe abdominal pain and may include hypertension, tachycardia, confusion, motor paralysis and seizures and may be life-threatening. AIP is estimated to affect 5.4 per million people in European countries [2].

The pathogenesis of the acute attacks is hypothesized to result from an overproduction of a hepatic neurotoxic metabolite, presumably δ-aminolevulinic acid (ALA) [3, 4]. This notion is consistent with the correction of the disease by liver transplantation in patients with severe AIP [5–9]. Moreover, when domino liver transplantations were performed, the recipients developed biological and clinical acute porphyrin attacks [10]. Altogether, these observations strongly support the hypothesis that the liver is the main organ involved in the pathogenesis of acute attacks.

The induction of the acute attacks is related to environmental or hormonal factors, such as cytochrome P450-inducing drugs, fasting, hormonal fluctuations during the menstrual cycle, infection or inflammation. These factors either directly induce the first enzyme of haem biosynthesis, δ-aminolevulinic acid synthase 1 (ALAS1), or increase the demand for haem synthesis in the liver and subsequently suppress the negative feedback of ALAS1. Carbohydrate loading, usually with intravenous glucose, may be an effective treatment in patients with uncomplicated acute attacks (without peripheral and central neurological signs or hyponatremia). Glucose administration, together with the resulting secondary increase in insulin, represses ALAS1 transcription via the inhibition of the transcriptional coactivator PGC-1alpha [11]. However, intravenous human hemin administration, which restores the free haem pool and the negative feedback of ALAS1, is, so far, the treatment of choice of acute attacks of porphyria. Early human hemin infusion is a highly effective treatment [12].

Acute intermittent porphyria is a low penetrance disorder. The penetrance has been estimated to be 23% in European countries [2]. Most symptomatic AIP patients experience a limited number of acute attacks in a lifetime, and the attacks often occur once and in all cases, the attacks are associated with clearly identified precipitating factors. However, a limited but significant number of patients become disabled by repetitive acute episodes with or without concomitant precipitating factors. These patients are treated with repeated haem infusions either to treat or to prevent acute attacks [13–17]. Some of these patients will even require monthly to weekly haem infusions. In Europe, approximately 5% of AIP patients suffer from recurrent attacks [2]. In addition to recurrent acute attacks, these chronic patients encounter many medical side effects and have markedly impaired quality of life [18]. The large majority of these patients respond well to haem therapy, but long-term treatment may induce a dependency on exogenous haem, a need for indwelling access due to alterations in the superficial venous system, a rare but severe thrombotic event [15, 16].

In this study, we followed up a cohort of 602 symptomatic patients, of whom 46 had recurrent AIP, to document the natural history of the occurrence of chronicity in AIP.

To elucidate the role of hemin in the recurrence of AIP attacks, we studied the hepatic transcriptome, serum proteome, liver macrophage polarization and oxidative and inflammatory profiles of an AIP mouse model which reproduces recurrent neurovisceral crisis treated by hemin. Moreover, thanks to the European Porphyrin Network (EPNET), we
extended the investigations to five human liver explants. We showed that chronic haem administration induces liver iron overload and sustains a strong oxidative stress response, which is known to activate haem oxygenase 1 (HO1). Surprisingly, in the AIP mouse model and human liver explants, we demonstrate that regular hemin administration induces chronic hepatic inflammation responsible of a HO1 induction remotely to haem administration that triggers ALAS1 and thus recurrence.

Materials and methods

Animal experiments

All animal experiments were performed according to procedures approved by the Bichat-Debré ethics committee. Animals were housed in a controlled environment with a 12-h light–dark cycle with free access to water and food. Animals were female C57BL/6 Hmbs<sup>-/-</sup> mice [19], 8 weeks old, weighing 20–25 g. Drugs (phenobarbital 100 mg kg<sup>-1</sup>, haem arginate 8 mg kg<sup>-1</sup>) were injected intraperitoneally. For each group, we treated six female mice (Fig. 2a). Every week, we treated the mice with phenobarbital for 3 days followed by a 2-day treatment with hemin (PB/HA group) or excipients (arginine, ethanol and propylene glycol) (PB/Excipients group) or saline (PB/Saline group). These treatments were repeated for 8 weeks. Another control group consisted of a noninduced group of mice injected everyday with saline (Saline group). When animals were sacrificed, liver tissues and blood samples were harvested.

Microarray analysis of gene expression in the mouse liver

The mouse liver transcriptome was analysed using Mouse Genome Survey Arrays v2.0 (Applied Biosystems, Foster City, CA, USA), containing 32 996 probes (60-mer oligonucleotide), which represented a set of 32 381 annotated mouse genes. A total of 12 independent experiments were performed for the two different biological conditions (PB/HA and PB/Saline groups). Transcriptome statistical analyses were performed similarly to those already described [20, 21].

Proteome study of mouse plasma

Two-dimensional electrophoresis (2-DE) was carried out on plasma samples using the IPGPhor Isoelectric Focusing System and the Ettan dalt six electrophoresis system (Amersham Biosciences, Little Chalfont, UK). Images of gels were digitized with a calibrated densitometer (GS-800, Bio-Rad, Hercules, CA, USA). Proteins of interest were manually excised and digested in-gel. Peptides were then identified either by peptide mass fingerprinting (MALDI-TOF MS, Voyager DE-PRO in reflectron mode, Applied Biosystems, Foster City, CA, USA) or by peptide sequencing using nano(n) ESI-IT MS/MS (Finnigan LCQ IT mass spectrometer, ThermoQuest, Finnigan MAT, San Jose, CA, USA).

Cytokine determination in mouse liver samples

After preparation, the levels of 10 mouse cytokines and chemokines in liver homogenates were simultaneously analysed using the MILLIPLEX<sup>®</sup> MAP Mouse Cytokine/Chemokine Magnetic Bead Panel (Millipore, Billerica, MA, USA), according to the manufacturer’s instructions. The 10 cytokines and chemokines that were analysed included Ifn-γ, Il-1β, Il-4, Il-6, Il-10, Il-12 (p40), Il-13, monocyte chemoattractant protein 1 (Mcp-1), macrophage inflammatory protein 1α (Mip-1α) and Tnf-α.

Myeloperoxidase and leukotriene measurement in the mouse liver

Mouse liver myeloperoxidase concentration was measured via ELISA (HK210, Hycult Biotech, Uden, Netherlands). Leukotriene E4 is a product of the 5-lipoxygenase pathway in activated mast cells, eosinophils and monocytes. The concentrations were determined in the mouse livers with a commercially available enzyme immunoassay kit, the Leukotriene E4 EIA Kit (Cayman Chemical, Ann Arbor, MI, USA).

Oxidative stress analysis of the mouse liver

The concentration of 8-isoprostan, a marker of lipid peroxidation, was determined in the mouse liver samples with a commercially available enzyme immunoassay kit, the 8-Isoprostane ELISA Kit (Cayman Chemical, Ann Arbor, MI, USA). The levels of reduced glutathione (GSH) and oxidized glutathione (GSSG) were measured via capillary electrophoresis using the CEfix<sup>™</sup>GSH kit (Analis, Suartée, Belgium) according to the manufacturer’s recommendations and the P/ACE<sup>™</sup> MDQ Capillary Electrophoresis system (Beckman Coulter, Brea, CA, USA). GSH/GSSG ratios were normalized according to the weight of the liver in each sample.
French cohort of AIP patients

Between 1974 and 2015, 602 symptomatic AIP patients were diagnosed at the French Center of Porphyria. The criteria for AIP diagnosis followed the EPNET guidelines. All patients presented with at least one acute attack that was biochemically confirmed by the presence of a massive excretion of urinary ALA and porphobilinogen (PBG). The porphyrin profile in urine, faeces and plasma samples allowed a differential diagnosis, eliminating both variegate porphyria and hereditary coproporphyria. The diagnosis was then confirmed by the presence of a 50% decrease in HMBS activity in erythrocytes and/or was complemented by the identification of a causative mutation in the HMBS gene via sequencing. From 1974 to 2015, a total of 46 patients were chronically affected by acute attacks and were defined as recurrent AIP patients according to the EPNET classification (four or more acute attacks for one or more years) [2]. These 46 patients required repeated IV infusions of human hemin either to treat or to prevent the occurrence of acute attacks.

Human liver samples

All procedures were performed in accordance with the 1983 and 2008 revisions of the Declaration of Helsinki, and the study was approved by the Institutional Review Board and the Hospital Ethics Committee of the Bichat University Hospital. Small pieces of liver from five AIP subjects from France, Sweden and Norway were obtained (Table S1). These five patients underwent orthotopic liver transplantation (OLT) due to the occurrence of recurrent and debilitating attacks that were responsible for a major deterioration in quality of life. Following OLT, urinary ALA and PBG levels rapidly normalized, and the attacks immediately stopped. Control liver tissues were obtained at the border of liver adenoma tumours from 10 non-AIP subjects.

More details and more materials and methods are provided in the Data S1.

Results

Natural history of AIP in France since 1974

Since the establishment of the French Center of Porphyria in 1974 and through 2015, 602 symptomatic AIP patients with at least one acute attack of porphyria were diagnosed (of whom 81% were female). A total of 88% of patients experienced a single acute crisis, 4.4% exhibited an intermittent crisis (between one and three acute attacks/year), and 7.6% (46 patients) were disabled by repetitive acute episodes (≥ four attacks/year), most of which occurred without obvious precipitating factors.

The number of AIP patients with recurrent acute attacks increased following the introduction of haem into the pharmacopoeia

In France, the administration of human hemin started in 1986. The number of AIP patients with recurrent attacks increased from 1.7% in 1985 (four recurrent AIP patients from a total of 230 AIP patients) before the introduction of hemin to 7.5% in 2008 (40 recurrent AIP patients from a total of 536 AIP patients). The ratio of recurrent patients has now stabilized to 7.6% (46 recurrent AIP patients from a total of 602 AIP patients) (Fig. 1). Recurrent AIP patients already existed before the introduction of human hemin, but after its introduction, the frequency of recurrent AIP increased by 4.4-fold, and the interval between crises shortened, in some cases to less than one week. Concerning the evolution of the 46 patients, 32 still exhibit recurrent AIP, of whom 18 patients receive human hemin as a preventive treatment every 7 to 14 days (before the appearance of any clinical symptoms), and most of them take oral opiate medication for daily pain treatment. In rare cases (n = 6), it has been possible to obtain complete cessation of human hemin treatment.

Fig. 1 Increasing numbers of AIP patients with recurrent acute attacks. The proportion of recurrent AIP patients has increased in the past 40 years in the French Center of Porphyria. Recurrent AIP patients already existed before the introduction of human hemin but at lower numbers.
Moreover, five patients underwent orthotopic liver transplantation (OLT) due to the presence of permanent pain and a poor quality of life (one patient died). Complete biochemical resolution was observed in the five patients after transplantation, and the four patients who are still living have remained attack-free up to now (3- to 8-year post-transplantation). On the 46 patients, a total of three patients died from unrelated diseases.

AIP mouse model and long-term treatment with hemin

To study the hepatic consequences of the chronic administration of hemin, we studied the Hmbs\textsuperscript{-/-} mouse model, which clinically develop a peripheral neuropathy as observed in some AIP patients [19, 22]. In this model, intraperitoneal injections of phenobarbital-induced Alas1 expression, resulting in a massive but transient overproduction of ALA and PBG without typical neurovisceral symptoms [19].

To reproduce recurrent attacks with frequent administration of human hemin, we set up a protocol of a chronic induction of an AIP crisis treated by hemin in the AIP mouse model (Fig. 2a). PBG level was measured in urines at weeks 1, 3, 6 and 8 (Fig. 2b). After the phenobarbital injection, the concentration of PBG increased and rapidly returned back to normal, as already described [23]. To further validate the biochemical induction of Alas1 in our model, we analysed the liver expression of Alas1 using Western blot analysis. When mice were sacrificed after the last phenobarbital injection on day 3 of the eighth week (PB/Saline D3 group), we observed a 15-fold overexpression of Alas1 when compared to noninduced mice (Saline group, Fig. 2c).

Paradoxical Alas1 induction after chronic hemin infusion in the liver of Hmbs\textsuperscript{-/-} mice

We analysed the protein expression of Alas1 in the liver of all groups of mice sacrificed at day 5 of the eighth week. As shown in Fig. 2c, 2 days after the last phenobarbital injection (PB/Saline group), Alas1 expression returned to the basal state, but surprisingly, after repeated haem treatment (PB/HA group), Alas1 expression in the liver was threefold higher than in noninduced (Saline group) and saline-treated mice (PB/Saline group).

Repeated hemin injection activated HO1 in the liver of Hmbs\textsuperscript{-/-} mice

Overexpression of the HO1 gene was observed in the liver in the haem arginate-treated group compared to all other groups (Fig. 2d). A ninefold induction was identified with microarrays, and an 11-fold increase was detected via quantitative RT-PCR, probably in response to the high cumulative dose of hemin. As shown by Western blot analysis, HO1 protein expression was also highly increased in the livers of mice treated with haem arginate compared to all other groups (Fig. 2e).

Repetitive hepatic genome-wide transcriptomic modulation after chronic haem arginate infusion in Hmbs\textsuperscript{-/-} mice

The liver transcriptome of two groups of Hmbs\textsuperscript{-/-} mice was analysed. Each group (n = 6) was treated sequentially for 8 weeks with phenobarbital and either treated with haem arginate (PB/HA group) or treated with saline (PB/Saline group). One hundred and fourteen probes were shown to be modulated by hemin treatment when using a P-value threshold of 0.1. Among these 114 probes, 43 transcripts were down-regulated, and 50 were up-regulated (Table S2). The extent of single probe modulation ranged from a fold change of 0.01 to 29.86. To interpret the biological significance of global gene modulation, we carried out functional enrichment analysis implemented by g:Profiler software [24]. Among the nine biological processes identified in silico, four were significantly enriched in genes belonging to biological pathways linked to inflammation (Table S3). Interestingly, several genes involved in reactive oxygen species metabolism were part of the transcriptomic picture of chronic haem administration, including (i) Cybb, which encodes a component of the phagocyte oxidase enzyme complex, (ii) Rac2, which augments the production of reactive oxygen species (ROS) by NADPH oxidase and (iii) glutathione S-transferase genes, which include genes such as Gstm3, Gstm4 and Gstp1. In addition, genes in the Bmp6-Id1 pathway controlling liver Hepcidin transcription were also induced. Altogether, these data of liver transcriptome showed that chronic hemin infusions in the mouse model significantly modified biological pathways linked to inflammation, oxidative stress and iron metabolism.

Repeated haem arginate infusions induce inflammation and oxidative stress in the liver of Hmbs\textsuperscript{-/-} mice

We further analysed a set of inflammatory and ROS markers in liver extract either at the mRNA or at the protein level. The expression of inflammatory cytokines was elevated in the liver of the mice treated by haem arginate (Table 1). The
myeloperoxidase (Mpo) level was markedly increased in the haem arginate group (5.9-fold; Fig. 3a), which suggests a polynuclear neutrophil infiltration in the liver. A high leukotriene level was also observed in the liver (11.8-fold in the haem arginate group; Fig. 3a). Markers of oxidative stress were also measured in the liver of all groups of mice. In the haem arginate group, the reduced...
oxidized glutathione ratio was decreased, and the level of 8-isoprostane was increased (0.3- and 12.9-fold, respectively; Fig. 3b) compared to the PB/Saline group.

To investigate the effect of chronic haem infusions at the systemic level, we analysed the plasma proteome in mice from the haem arginate group compared to the PB/Saline group. The analysis revealed that 11 plasma proteins were differentially expressed (Table S4), among which four were acute phase proteins either up-regulated (Serum amyloid P component, Complement C3 and Haptoglobin) or down-regulated (Transthyretin).

Repeated haem arginate infusions induce iron overload in the liver of Hmbs<sup>−/−</sup> mice

Repeated hemin injections and its degradation by HO1 release large amounts of iron. By measuring the liver iron content in treated mice, we showed a modest but significantly higher iron content than in nonhemin-treated mice (Figure S1a). The liver transcription profile of the mice also showed an overexpression of two genes in the haem arginate group, Bmp6 and Id1, which were first identified by microarray analysis and subsequently confirmed by qRT-PCR (Figure S1b). Bmp6 and Id1 genes were described to belong to the same pathway of hepcidin regulation [25]. This pathway is activated in response to iron overload [25].

Metabolic changes in the liver of recurrent AIP patients who receive frequent hemin administration

Explanted livers from five recurrently afflicted AIP patients were studied. All five patients received a large amount of human hemin before transplantation at a frequency ranging from once a week to once a month. The last infusion before OLT took place 3 h before in two patients (patients P4 and P5), approximately 24 h before for one patient (patients P2), 3 days before in patient P1 and 4 days before in patient P3 (Table S1).

Histologically, liver architecture was preserved in all patients without any significant portal fibrosis or inflammation. However, an increased number of

### Table 1 Expression of cytokines and macrophage differentiation markers in the livers of hemin-treated mice (PB/HA group) compared to mice treated with saline (PB/Saline group)

| Gene            | mRNA level | Protein level | Fold change | P  |
|-----------------|------------|---------------|-------------|----|
| Proinflammatory markers/M1 macrophage polarization |            |               |             |    |
| Il-1            | x          | 1.3           | NS          |    |
| Infγ            | x          | 0.8           | NS          |    |
| Il-4            | x          | 1.9           | NS          |    |
| Il-1β           | x          | 1.3           | 0.0260      |    |
| Il-6            | x          | 3.3           | 0.0022      |    |
|                 | x          | 1.7           | 0.0411      |    |
| Il-12p40        | x          | 2.6           | 0.0260      |    |
| Tnfx3           | x          | 3.0           | 0.0087      |    |
|                 |            | 1.3           | 0.0600      |    |
| Anti-inflammatory markers/M2 macrophage polarization |            |               |             |    |
| Arg1            | x          | 1.0           | NS          |    |
| Il-10           | x          | 3.3           | 0.0022      |    |
|                 |            | 1.7           | 0.0900      |    |
| Il-13           | x          | 4.1           | 0.0411      |    |
| Mrc1            | x          | 1.5           | 0.0022      |    |
| Mgl1            | x          | 1.8           | 0.0022      |    |
| Atf1            | x          | 1.2           | 0.0159      |    |
| Cd91            | x          | 1.2           | 0.0550      |    |
| Cd163           | x          | 1.6           | 0.0317      |    |
| HO1             | x          | 11.7          | 0.0022      |    |
|                 |            | 6.5           | 0.0238      |    |

NS, not significant (P > 0.1). Genes that are significantly overexpressed are in bold.
lobular inflammatory foci was observed in all cases (≥2 foci; Fig. 4a). Immunophenotypical analysis demonstrated an increased number of intrasinusoidal MPO, CD68-positive macrophages and CD206-positive M2 macrophages in the inflammatory foci suggestive of inflammatory leucocytes infiltration (Fig. 5a-c).

In all explants, we observed a fourfold mean increased level of \( \text{HO1} \) mRNA compared to mean levels from 10 control livers (Fig. 6a). At the protein level, \( \text{HO1} \) is significantly overexpressed in the explanted livers of four patients of five. Although patients P1 and P3 did not receive hemin during the 3 to 4 days preceding surgery, \( \text{HO1} \) was maintained at a high level.

In all explants, \( \text{ALAS1} \) mRNA levels were in the lower range of the control values (Fig. 6a). In contrast, Western blot analyses revealed a significant overexpression of \( \text{ALAS1} \) in the liver of all AIP patients compared to controls \( (P = 0.035, \text{Fig. 6a}) \). P4 and P5 patients showed the highest induction of \( \text{ALAS1} \).

Perls’ blue staining was performed on samples from three patients and showed important iron deposits in hepatocytes and in Kupffer cells (Fig. 4b). Moreover, the iron status of 27 recurrent patients with frequent administration of haem arginate was collected. Median ferritin was 696 \( \mu \text{g} \text{L}^{-1} \) (range: 21–2277) (Table 2), which was above the reference value in 85% of the patients. Twelve patients underwent liver magnetic resonance imaging; of these, 11 of them had confirmed iron overload, and the iron liver content was above 230 \( \mu \text{mol} \text{g}^{-1} \) \( (N < 30) \) in five patients. Twelve patients are currently being treated with serial phlebotomies or chelator administration.

**Discussion**

Today, the main issue in the medical care of AIP patients is the debilitating condition of patients who present with recurrent attacks. In Europe, 3% to 5% of individuals with AIP experienced repeated acute attacks [2]. This follow-up studies showed, for the first time, that this percentage reached 7.6% in France. This situation was rare before the introduction of human hemin, and in France, we observed a 4.4-fold increase in the number of recurrent attacks over 30 years beginning with the introduction of haem arginate to the pharmacopeia. All these patients received repeated hem arginate infusion either to treat recurrent acute crises or as a preventive treatment for recurrent attacks.

An acute porphyria attack is considered to be the consequence of an increase in hepatic \( \text{ALAS1} \) activity that results in the accumulation of the putatively neurotoxic haem precursors ALA and PBG [3]. Hepatic \( \text{ALAS1} \) expression is controlled via negative feedback regulation by the intracellular-free haem pool. This regulation occurs at the transcriptional level [26, 27] and mainly by the modulation of the mitochondrial translocation of \( \text{ALAS1} \) [28]. \( \text{HO1} \), the key enzyme in haem degradation, is one of the major determinants of the level of intracellular-free haem. Haem induces its own catabolism by inhibiting the transcriptional repressor \( \text{BACH1} \), allowing the transcription of \( \text{HO1} \) [29].

To date, no study has evaluated the occurrence of chronicity in AIP and experimentally explored the consequences of chronic exogenous haem therapy on the liver. We elucidate the impact of chronic haem administration on the liver in a model of \( \text{Hmbs}^{-/-} \) mice. We then extended the
investigations to five human-explanted livers from recurrent AIP patients.

In *Hmbs* −/− mice treated repeatedly with haem arginate, HO1 was strongly induced in the liver both at the mRNA (11-fold) and at the protein levels (6.5-fold). This induction exacerbated haem catabolism and secondarily increased Alas1 expression. In the five explanted livers of AIP patients, *HO1* mRNA expression was also increased (four-fold). These patients had received large amount of therapeutic hemin prior to OLT and have induced HO1 response through the BACH1/NRF2 pathway. At the protein level, HO1 is overexpressed in all patients except one. Haem arginate half-life is assumed to be 10–11 h [30] and two patients, P1 and P3, received their last infusion more than five times the half-life. Figure 6a shows that although haem arginate was totally cleared from blood, the two patients exhibited a high level of HO1 induction that could not be due to the last haem arginate infusion exclusively and may represent a chronic adaptation. Also, consistent with the results of the mouse study, increased expression of ALAS1 was observed chronically in all explanted livers of AIP patients, at the protein level without mRNA induction which is in favour of a post-transcriptional regulatory mechanism.

Liver extracts of haem-treated mice exhibited high levels of proinflammatory cytokines Tnfα, Il-6, Il-1β and Il-12p40. This pattern is a hallmark of MyD88/TLR4 activation by haem [31]. Likewise, we observed a high expression level of S100A, S100B and Marco proteins. All these results are consistent with an M1 polarization of proinflammatory infiltrative macrophages in the liver. Evidence of a proinflammatory role for haem *in vivo* was also observed by Wagener *et al.* [32] after a single-dose hemin infusion into the tail veins of BALB/c wild-type mice, leading to the infiltration of leukocytes in the liver. Unlike our protocol, this study utilized a single high dose of hemin, whereas in the present study, we investigated the effects of a cumulative dose of hemin over a 2-month period and observed chronic and complex inflammatory lesions.

The liver extracts from haem-treated mice also showed an increased expression of Mrc1, Mgl1 and the Il-10 anti-inflammatory cytokines, which were suggestive of M2 polarization of macrophages.

---

*Fig. 4* Liver iron overload in AIP patients receiving frequent human hemin administration. (a) HES staining (× 200) showing normal liver architecture with a nonfibrous portal tract (PT) and the presence of intralobular inflammatory cells (arrows). (b) Perls’ staining (× 200) showing macrophage and hepatocyte iron accumulation.
Human-explanted livers from AIP patients also highly expressed MRC1 (CD206), which was compatible with a M2 polarization. One distinguishing characteristic between M2 and M1 macrophage polarization is the intracellular redox status [33]. The oxidation status observed in liver extracts of haem-treated mice is characteristic of an M2 polarization (a reduced GSH/GSSG ratio, a high level of 8-isoprostane and an induction of Cybb and Rac2; Fig. 3b and Table S2). Altogether, these data support the idea of a complex inflammatory pattern consisting of an M1/Th1 proinflammatory pattern associated with a predominant M2/Th2 anti-inflammatory response, according to the oxidation status. Several studies showed that the anti-inflammatory cytokine IL-10 induces HO1 [34–36] which could amplify the effects of haem per se on HO1 expression.

Also, notable was the observation of the presence of iron deposition in livers of both haem-treated mice and AIP patients exposed to chronic haem infusions (Figures S1 and 4b). Repeated hemin infusion is responsible for a high cumulative dose of iron (Table 2). Marsden et al. [15] have shown that there was a significant correlation between the serum ferritin concentration and number of doses that were administered. In the explanted livers, iron overload was observed both in hepatocytes and in Kupffer cells where it presented as large aggregates. In fact, Vinchi et al. [37] showed that during intravascular hemolysis leading to free haem excess, the liver is the most susceptible organ to haem overload, and when hemopexin capacity is exceeded, haem accumulates mainly in Kupffer cells. In line with our results, three well-documented studies concerning recurrent AIP patients reported also that regular hemin infusions trigger variable liver iron overload [8, 9, 38].

Different studies have shown that iron overload impairs the hepatic mitochondrial metabolism [39, 40]. High amount of free iron released by HO-1 catalyses the formation of reactive oxygen species and is responsible for alteration of mitochondrial respiration in rodent submitted to systemic inflammation [41]. Thus, liver iron overload, as observed in recurrent AIP patient, could worsen the impairment of the respiratory chain and the tricarboxylic acid cycle of the liver mitochondrias during an acute attack, as previously shown in the AIP mouse model [42].

Oxidative stress, as observed in Fig. 3b, induces the dissociation of the stress-sensitive KEAP1 protein from NRF2. In turn, NRF2 translocates to the
nucleus and then transactivates HO1 expression through the AREs sequences and consequently enhances endogenous free haem degradation [43].

Conclusion
AIP is considered as an intermittent disease, but 7.6% of patients have a chronic life-threatening debilitating condition. Our study highlights a key role of hemin infusions in the pathophysiology of AIP chronic attacks. Nevertheless, hemin is the most effective treatment for acute neurovisceral attacks and is life-saving. The introduction of haem arginate decreased mortality at a price of increasing recurrent attacks. Hemin treatment needs therefore to be restricted to patients with severe forms of AIP crises with the occurrence of progressive signs of a central or peripheral neurological alteration, profound hyponatremia or hyperalgesic acute crisis unresponsive to symptomatic treatment. Altogether,

Fig. 6 HO1 and ALAS1 activation in the liver samples of recurrent AIP patients. (a) HO1 mRNA is highly increased in the liver of recurrent AIP patients who had a liver transplantation (n = 5) when compared to controls (n = 10, healthy tissue around hepatic adenoma from nonporphyric patients). At the protein level, HO1 was induced in the liver of four patients of five. ALAS1 protein is significantly overexpressed in all the explanted livers of recurrent AIP patients (n = 5) when compared to controls (n = 10). ALAS1 mRNA exhibited no difference between AIP patients and control, which underlines the predominant regulation of ALAS1 at the post-transcriptional level. All AIP patients had been treated with human hemin between 3 and 96 h before transplantation. (b) Schema of the hypothetical mechanism of HO1 induction in the liver of AIP patients after cumulative doses of hemin. The three factors that could be implicated in HO1 induction are haem per se, the inflammation characterized by an adaptive M2 macrophage polarization promoting the IL-10-HO1 amplifying loop and the oxidative stress generated by iron overload.
we bring convergent arguments showing that chronic exogenous haem infusions were responsible for a physiological response which activates chronically HO1 expression. The three factors that could be implicated in HO1 induction are haem per se, the inflammation characterized by an adaptive M2 macrophage polarization promoting the IL-10-HO1 amplifying loop and the oxidative stress generated by iron overload (Fig. 6b). In the context of AIP, exacerbated free haem degradation would reduce the free haem pool, which in turn would up-regulate ALAS1, promote ALA and PBG overproduction and finally, exacerbate porphyric symptoms. In humans, the HO1 promoter contains a (GT)(n) dinucleotide repeat that is related to HO1 expression and activity, and it would be tempting to speculate that this polymorphism could modulate the basal level of the free haem pool and in turn

Table 2: Iron status of 27 AIP patients with frequent administration of haem arginate

| Sex | Age of diagnosis | Haem arginate treatment (250 mg) | Ferritin µg L\(^{-1}\) | Liver MRI | Iron liver content µmol g\(^{-1}\) (N < 30) | Serial phlebotomies | Chelator treatment |
|-----|------------------|---------------------------------|----------------------|-----------|-------------------------------------|-------------------|-------------------|
| F   | 29               | 26                              | MX2 - MX4            | 2277      | 230: high overload                  | +                 |                   |
| F   | 62               | 53                              | M - MX2              | 1962      | 260: high overload                  | +                 |                   |
| F   | 50               | 30                              | MX3                  | 1360      | Moderate overload                   | No (due to low Hb) |                   |
| F   | 56               | 34                              | MX3                  | 1329      | 290: high overload                  | +                 |                   |
| F   | 42               | 30                              | MX4                  | 1203      | 240: high overload                  | +                 |                   |
| F   | 37               | 21                              | MX8                  | 1200      |                                     |                   | +                 |
| M   | 49               | 34                              | MX4                  | 1003      | +                                   |                   |                   |
| F   | 50               | 40                              | MX4                  | 986       |                                     | +                 |                   |
| M   | 48               | 32                              | MX4                  | 975       | 90: mild overload                   | +                 |                   |
| F   | 43               | 22                              | MX2                  | 900       | 270: high overload                  | +                 |                   |
| F   | 66               | 60                              | When crisis          | 886       | +                                   |                   |                   |
| F   | 41               | 33                              | MX8                  | 700       |                                      |                   |                   |
| F   | 39               | 20                              | MX4                  | 630       |                                      | +                 |                   |
| F   | 51               | 29                              | M - MX3              | 621       | 90: mild overload                   |                   |                   |
| F   | 43               | 27                              | MX3                  | 542       | Mild overload                       | +                 |                   |
| F   | 38               | 34                              | MX3                  | 436       | 100: moderate overload              |                   |                   |
| M   | 54               | 37                              | M                    | 384       | 130: moderate overload              | +                 |                   |
| F   | 33               | 18                              | MX4                  | 316       |                                      |                   |                   |
| F   | 45               | 34                              | When crisis          | 253       |                                      |                   |                   |
| F   | 49               | 38                              | MX2                  | 198       |                                      |                   |                   |
| F   | 59               | 22                              | When crisis          | 190       |                                      |                   |                   |
| F   | 43               | 21                              | MX2 - MX3            | 161       | 25: No overload                     |                   |                   |
| F   | 33               | 30                              | When crisis          | 112       |                                      |                   |                   |
| F   | 36               | 29                              | When crisis          | 73        |                                      |                   |                   |
| F   | 27               | 22                              | MX2                  | 44        |                                      |                   |                   |
| F   | 34               | 26                              | When crisis          | 40        |                                      |                   |                   |
| F   | 34               | 23                              | When crisis          | 21        |                                      |                   |                   |
| Mean|                  |                                 |                      |           |                                     |                   | 696               |

*Dosage schedule of haem arginate. M, monthly, MX2, twice per month, MX3, three times per month, MX4, four times per month, MX8, eight times per month. NP, not performed. Iron overloads confirmed by liver MRI are in bold.*
the penetrance and the severity of AIP. The present data that demonstrate the role of chronic inflammation on HO1 activation after repeated haem therapy is crucial for the improvement of recurrent AIP patient care. Subsequent development of new and safe ALAS1 and/or HO1 inhibitors would greatly improve AIP treatment.

**Conflict of interest statement**

LG, JCD, PH, ES and AKA were funded for attending meeting related to ongoing clinical trial by Alnylam Pharmaceuticals. Other authors have no conflict of interest to declare.

**Acknowledgements**

We are very grateful to Professor Urs Meyer and Doctor Anne-Kathrin Peyer for having provided the living *Hmbs*-/- mice, to Eric Couchi for his excellent supervision of animal breeding and treatments and to Sylvie Simonin for urinary ALA and PBG measurements.

**References**

1. Puy H, Gouya L, Deybach JC. Porphyrias. *Lancet* 2010; **375**: 924–37.
2. Elder G, Harper P, Badminton M, Sandberg S, Deybach JC. The incidence of inherited porphyrias in Europe. *J Inherit Metab Dis* 2013; **36**: 849–57.
3. Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. *Semin Liver Dis* 1998; **18**: 43–52.
4. Sima AA, Kennedy JC, Blakeslee D, Robertson DM. Experimental porphyrin neuropathy: a preliminary report. *Can J Neurol Sci* 1981; **8**: 105–13.
5. Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. *Lancet* 2004; **363**: 705–6.
6. Wahlin S, Harper P, Sardh E, Andersson C, Andersson DE, Ericzon BG. Combined liver and kidney transplantation in acute intermittent porphyria. *Transpl Int* 2010; **23**: e18–21.
7. Dar FS, Asai K, Haque AR, Cherian T, Rela M, Heaton N. Liver transplantation for acute intermittent porphyria: a viable treatment? *Hepatobiliary Pancreat Dis Int* 2010; **9**: 93–6.
8. Dowman JK, Gunson BK, Mirza DF, Bramhall SR, Badminton MN, Newsome PN. Liver transplantation for acute intermittent porphyria is complicated by a high rate of hepatic artery thrombosis. *Liver Transpl* 2012; **18**: 195–200.
9. Yasuda M, Erwin AL, Liu LU, et al. Liver transplantation for acute intermittent porphyria: biochemical and pathologic studies of the explanted liver. *Mol Med* 2015; **21**: 487–95.
10. Dowman JK, Gunson BK, Bramhall S, Badminton MN, Newsome PN. Liver transplantation from donors with acute intermittent porphyria. *Ann Intern Med* 2011; **154**: 571–2.
11. Handschin C, Lin J, Rhee J, et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. *Cell* 2005; **122**: 505–15.
12. Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. *Medicine (Baltimore)* 2005; **84**: 48–60.
13. Anderson KE, Collins S. Open-label study of hemin for acute porphyria: clinical practice implications. *Am J Med* 2006; **119**: 801.e819–24.
14. Bonkovsky HL, Maddukuri VC, Yazici C, et al. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium. *Am J Med* 2014; **127**: 1233–41.
15. Marsden JT, Guppy S, Stein P, et al. Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms. *JIMD Rep* 2015; **22**: 57–65.
16. Pischik E, Kauppinen R. An update of clinical management of acute intermittent porphyria. *Appl Clin Genet* 2015; **8**: 201–14.
17. Stein P, Badminton M, Barth J, Rees D, Stewart MF. Best practice guidelines on clinical management of acute attacks of porphyria and their complications. *Ann Clin Biochem* 2013; **50**: 217–23.
18. Naik HSM, Sanderson SC, Balwani M, Desnick RJ. Experiences and concerns of patients with recurrent attacks of acute hepatic porphyria: A qualitative study. *Mol Gen Metab* 2016; **119**: 278–83.
19. Lindberg RL, Porcher C, Grandchamp B, et al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. *Nat Genet* 1996; **12**: 195–9.
20. Diamond D, Krasnoselsky A, Burnum K, et al. Proteome and computational analyses reveal new insights into the mechanisms of hepatitis C virus-mediated liver disease posttransplantation. *Hepatology* 2012; **56**: 28–38.
21. Rasmussen A, Tchitchek N, Susnow N, et al. Early transcriptional programming links progression to hepatitis C virus-induced severe liver disease in transplant patients. *Hepatology* 2012; **56**: 17–27.
22. Lindberg RL, Martini R, Baumgartner M, et al. Motor neuropathy in porphobilinogen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. *J Clin Invest* 1999; **103**: 1127–34.
23. Schuurmans MM, Hoffmann F, Lindberg RL, Meyer UA. Zinc mesoporphyrin represses induced hepatic 5-aminolevulinic acid synthase and reduces heme oxygenase activity in a mouse model of acute hepatic porphyria. *Hepatology* 2001; **33**: 1217–22.
24. Reimand J, Kull M, Peterson H, Hansen J, Vilo J. gProFile—a web-based toolset for functional profiling of gene lists from large-scale experiments. *Nucleic Acids Res* 2007; **35**: W193–200.
25. Kautz L, Meynard D, Monnier A, et al. Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad 7, Id1, and Atoh8 in the mouse liver. *Blood* 2008; **112**: 1503–9.
Recurrent attacks of acute hepatic porphyria / C. Schmitt et al.

26 Gotoh S, Nakamura T, Kataoka T, Taketani S. Egr-1 regulates the transcriptional repression of mouse delta-aminolevulinic acid synthase 1 by heme. Gene 2011; 472: 28–36.

27 Yamamoto M, Kure S, Engel JD, Hiraga K. Structure, turnover, and heme-mediated suppression of the level of mRNA encoding rat liver delta-aminolevulinate synthase. J Biol Chem 1988; 263: 15973–9.

28 Lathrop JT, Timko MP. Regulation by heme of mitochondrial oxidative metabolism in rats with chronic arginate infusions in liver samples of AIP mice.

36 Ricchetti GA, Williams LM, Foxwell BM. Heme oxygenase 1 expression induced by IL-10 requires STAT-3 and phosphoinositol-3 kinase and is inhibited by lipopolysaccharide. J Leukoc Biol 2004; 76: 719–26.

38 Willandt B, Langendonk JG, Biermann K, et al. Liver fibrosis associated with iron accumulation due to long-term heme-arginate treatment in acute intermittent porphyria: a case series. JIMD Rep 2015; 25: 77–81.

39 Bacon B, Park C, Brittenham G, O'Neill R, Tavill A. Hepatic mitochondrial oxidative metabolism in rats with chronic dietary iron overload. Hepatology 1985; 5: 789–97.

40 Volani C, Doerrier C, Demetz E, et al. Dietary iron loading negatively affects liver mitochondrial function. Metallomics 2017; 9: 1634–44.

41 Duvinageau J, Piskernik C, Haindl S, et al. A novel endotoxin-induced pathway: upregulation of heme oxygenase 1, accumulation of free iron, and free iron-mediated mitochondrial dysfunction. Lab Invest 2008; 88: 70–7.

42 Homedan C, Laafi J, Schmitt C, et al. Acute intermittent porphyria causes hepatic mitochondrial energetic failure in a mouse model. Int J Biochem Cell Biol 2014; 51: 93–101.

43 Naito Y, Takagi T, Higashimura Y. Heme oxygenase-1 and anti-inflammatory M2 macrophages. Arch Biochem Biophys 2014; 564: 83–8.

Correspondence: Laurent Gouya, Centre Français des Porphyries, Hôpital Louis Mourier, AP-HP, 178 rue des Renouillers, 92701 Colombes, France.

(fax: +33 1 47 60 67 03; e-mail: laurent.gouya@inserm.fr).

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Haem arginate infusion in recurrent AIP patients who underwent a liver transplantation.

Table S2. Hepatic genome-wide transcriptomic analysis after chronic haem arginate infusion in Hmbs–/– mice.

Table S3. Classification of the transcripts according to biological process.

Table S4. Proteome analysis after chronic haem arginate infusions in Hmbs–/– mice.

Figure S1. Iron overload in the liver samples of AIP mouse model treated chronically with human hemin.

Data S1. Materials and Methods.